MR-HIFU for Bone Metastases
- Conditions
- Bone MetastasesCancer
- Interventions
- Device: Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)
- Registration Number
- NCT01964677
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Brief Summary
The aim of this study is to evaluate effectiveness of the Philips Sonalleve MR-HIFU device for the palliation of pain in patients with bone metastases.
Magnetic Resonance Imaging-guided High Intensity Focused Ultrasound (MR-HIFU) uses ultrasound to palliate pain caused by bone metastases. The main palliative mechanism of the method is due to local bone denervation, caused by the heat denaturation of the periosteum layer in the treated area. The importance of this therapy is that it offers a non-invasive, focal therapy, avoiding side-effects to surrounding normal tissue that occur with radiation therapy or the need for needle insertion as with radio-frequency(RF)ablation.
The study hypothesis is that MR-HIFU will be effective in treating the pain associated with bone metastases
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 12
- radiologic evidence of bone metastases from any solid tumour
- diagnosis of dominant painful bone metastasis
- target lesion less than 8cm
- primary bone tumours rather than metastases
- Inability to tolerate stationary position during treatment
- pregnancy
- MRI incompatible metal implants
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description MR-HIFU of painful bone metastases Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU) -
- Primary Outcome Measures
Name Time Method Pain response 30 days post-treatment
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
The Royal Marsden NHS Foundation Trust
🇬🇧Sutton, Surrey, United Kingdom